EU releases guidance for medicine shortages
The EU has issued two guidance documents intended to advise the pharmaceutical industry and patients during medicinal shortages.
List view / Grid view
The EU has issued two guidance documents intended to advise the pharmaceutical industry and patients during medicinal shortages.
Vizimpro (dacomitinib) has been recommended as a first-line treatment option for patients with lung cancer.
New regulations and legislations are being formed in the US to combat healthcare costs, including drug prices.
The DHSC has announced their plans for pharmaceutical transportation in the case of a no-deal Brexit.
A research group has designed a pills-on-a-coil system to administer drugs without having to take pills.
A pharmaceutical company will appeal a decision by NICE to not recommend osimertinib for use within NHS England.
Accelerated approval has been granted to Xpovio to treat refractory multiple myeloma by the FDA.
A Phase III clinical development programme testing otilimab in patients with RA has begun.
A study has shown that crystallising drugs removes localised immune reaction, allowing long-term release of drugs from medical devices.
New guidance drafts have been announced by the FDA to improve patients understanding and keep information consistent.
ABPI Chief Executive, Mike Thompson, will retire at the end of 2019.
All sponsors of clinical trials conducted in the European Union have been reminded of their obligation to make summaries of trial results.
The filler market is predicted to increase to US$2 billion by 2024, according to a new report.
Three API re-packers who failed to meet current good manufacturing practice requirements have received warning letters from the FDA.
A recent report has presented an argument for updating vaccine development during health emergencies to increase efficiency.